HDM201 + ancillary treatment
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid and Hematological TP53wt Tumors
Conditions
Advanced Solid and Hematological TP53wt Tumors
Trial Timeline
Jul 7, 2014 → Jun 9, 2020
NCT ID
NCT02143635About HDM201 + ancillary treatment
HDM201 + ancillary treatment is a phase 1 stage product being developed by Novartis for Advanced Solid and Hematological TP53wt Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02143635. Target conditions include Advanced Solid and Hematological TP53wt Tumors.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02143635 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Solid and Hematological TP53wt Tumors